The extensive pharmacological evaluation of JL 13 as an atypical antipsychotic drug has revealed a close similarity to clozapine, however with some major advantages. JL 13 was characterized as a weak D 2 antagonist, both in vitro and in vivo, with a strong affinity for the D 4 and the 5-HT 2A receptors. It has no affinity for the 5-HT 2C receptor. In vivo microdialysis experiments in rat showed that JL 13, like clozapine, preferentially increased extracellular dopamine concentrations in the prefrontal cortex compared to nucleus accumbens or striatum.
